To be clear on 21 Sep 2023 we had results for Bis + Dox (86% improvement when used in combo) and now Bis + Dec (92% in combo) both screened in 143 cell lines.So we have shown excellent preclinical efficacy in the most broadly used cancer treatments in solid and blood tumours.
@reon1- if I understand this correctly, this research further supports the investigator initiated AML trials in Australia and not a separate set of AML trials.
Otsuka, the ball is in your court.
Ann: Bisantrene with Decitabine Enhances Cancer Cell Killing, page-10
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.61 |
Change
-0.080(4.73%) |
Mkt cap ! $277.7M | |||
| Open | High | Low | Value | Volume |
| $1.66 | $1.66 | $1.57 | $275.0K | 168.9K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 625 | $1.60 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.62 | 650 | 1 |
View Market Depth
| Last trade - 14.51pm 04/10/2024 (20 minute delay) ? |
| RAC (ASX) Chart |